Catalyst
Slingshot members are tracking this event:
Ophthotech (OPHT) Announces the Publication of Fovista in Combination with Lucentis Phase 2b Study Results in Ophthalmology, the Journal of the American Academy of Ophthalmology
Do you think this event is important to the companies below? How will it affect their stock price?
Related Companies | Importance
|
Impact on Stocks
|
||||
---|---|---|---|---|---|---|
OPHT |
|
|
Additional Information
The article in Ophthalmology from this prospective, randomized, controlled Phase 2b clinical trial of 449 patients with wet AMD, indicates that Ophthotech's Fovista® (1.5 mg), administered in combination with Lucentis®, met the pre-specified primary efficacy endpoint of mean change in visual acuity. Patients receiving the combination of Fovista® (1.5 mg) and Lucentis® (0.5 mg) gained a mean of 10.6 letters of vision on the ETDRS standardized chart at 24 weeks, compared to 6.5 letters for patients receiving Lucentis® monotherapy (p=0.019). This represents a 62% additional benefit from baseline. No significant safety issues were observed for either treatment group in the trial.
Slingshot Insights Explained
Catalyst Date
Occurred on:
Oct 31, 2016
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Fovista, Lucentis